TY - JOUR
T1 - Fatigue is highly prevalent in patients with COPD and correlates poorly with the degree of airflow limitation
AU - Goertz, Yvonne M. J.
AU - Spruit, Martijn A.
AU - Van't Hul, Alex J.
AU - Peters, Jeannette B.
AU - Van Herck, Maarten
AU - Nakken, Nienke
AU - Djamin, Remco S.
AU - Burtin, Chris
AU - Thong, Melissa S. Y.
AU - Coors, Arnold
AU - Meertens-Kerris, Yvonne
AU - Wouters, Emiel F. M.
AU - Prins, Judith B.
AU - Franssen, Frits M. E.
AU - Muris, Jean W. M.
AU - Vanfleteren, Lowie E. G. W.
AU - Sprangers, Mirjam A. G.
AU - Janssen, Daisy J. A.
AU - Vercoulen, Jan H.
N1 - Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: This project is supported by the Lung foundation Netherlands, Leusden, the Netherlands (grant numbers 4.1.16.085 and 3.4.12.024); AstraZeneca, the Netherlands; Boehringer Ingelheim, the Netherlands; Stichting Astma Bestrijding, the Netherlands; Hasselt University, Belgium; and CIRO, the Netherlands.
Publisher Copyright:
© The Author(s), 2019.
PY - 2019/9
Y1 - 2019/9
N2 - Background: The objective of this study was to compare fatigue levels between subjects with and without COPD, and to investigate the relationship between fatigue, demographics, clinical features and disease severity. Methods: A total of 1290 patients with COPD [age 65 +/- 9 years, 61% male, forced expiratory volume in 1 s (FEV1) 56 +/- 19% predicted] and 199 subjects without COPD (age 63 +/- 9 years, 51% male, FEV1 112 +/- 21% predicted) were assessed for fatigue (Checklist Individual Strength-Fatigue), demographics, clinical features and disease severity. Results: Patients with COPD had a higher mean fatigue score, and a higher proportion of severe fatigue (CIS-Fatigue score 35 +/- 12 versus 21 +/- 11 points, p <0.001; 49 versus 10%, p <0.001). Fatigue was significantly, but poorly, associated with the degree of airflow limitation [FEV1 (% predicted) Spearman correlation coefficient=-0.08, p = 0.006]. Multiple regression indicated that 30% of the variance in fatigue was explained by the predictor variables. Conclusions: Severe fatigue is prevalent in half of the patients with COPD, and correlates poorly with the degree of airflow limitation. Future studies are needed to better understand the physical, psychological, behavioural, and systemic factors that precipitate or perpetuate fatigue in COPD.
AB - Background: The objective of this study was to compare fatigue levels between subjects with and without COPD, and to investigate the relationship between fatigue, demographics, clinical features and disease severity. Methods: A total of 1290 patients with COPD [age 65 +/- 9 years, 61% male, forced expiratory volume in 1 s (FEV1) 56 +/- 19% predicted] and 199 subjects without COPD (age 63 +/- 9 years, 51% male, FEV1 112 +/- 21% predicted) were assessed for fatigue (Checklist Individual Strength-Fatigue), demographics, clinical features and disease severity. Results: Patients with COPD had a higher mean fatigue score, and a higher proportion of severe fatigue (CIS-Fatigue score 35 +/- 12 versus 21 +/- 11 points, p <0.001; 49 versus 10%, p <0.001). Fatigue was significantly, but poorly, associated with the degree of airflow limitation [FEV1 (% predicted) Spearman correlation coefficient=-0.08, p = 0.006]. Multiple regression indicated that 30% of the variance in fatigue was explained by the predictor variables. Conclusions: Severe fatigue is prevalent in half of the patients with COPD, and correlates poorly with the degree of airflow limitation. Future studies are needed to better understand the physical, psychological, behavioural, and systemic factors that precipitate or perpetuate fatigue in COPD.
KW - airway obstruction
KW - chronic obstructive pulmonary disease
KW - fatigue
KW - OBSTRUCTIVE PULMONARY-DISEASE
KW - QUALITY-OF-LIFE
KW - HEALTH-STATUS
KW - SYSTEMIC INFLAMMATION
KW - SUBJECTIVE FATIGUE
KW - PHYSICAL-ACTIVITY
KW - POPULATION
KW - SYMPTOMS
KW - DEPRESSION
KW - IMPACT
U2 - 10.1177/1753466619878128
DO - 10.1177/1753466619878128
M3 - Article
C2 - 31558115
SN - 1753-4658
VL - 13
JO - Therapeutic Advances in Respiratory Disease
JF - Therapeutic Advances in Respiratory Disease
M1 - 1753466619878128
ER -